LFG
KYTX icon

Larson Financial Group’s Kyverna Therapeutics KYTX Stock Holding History

Larson Financial Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$345 Buy
+40
New +$333 ﹤0.01% 3384

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Larson Financial Group's KYTX Position: Q1 2026 in Review

Larson Financial Group opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 40 shares worth $345. The stake represents ﹤0.01% of the portfolio and ranks #3384 among its holdings.

111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Larson Financial Group held 40 shares of Kyverna Therapeutics worth $345 as of Q1 2026.
  • Kyverna Therapeutics was a new Larson Financial Group position in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3384 holding.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.